Search This Blog

Tuesday, August 4, 2020

Jazz Pharmaceuticals EPS beats by $0.60, beats on revenue

Jazz Pharmaceuticals (NASDAQ:JAZZ): Q2 Non-GAAP EPS of $3.71 beats by $0.60; GAAP EPS of $2.06 beats by $0.21.
Revenue of $562.4M (+5.3% Y/Y) beats by $59.21M.
R&D $78.9M vs. $63.7M consensus.
Press Release

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)